Glycophos

Glycophos is a sodium glycerophosphate pentahydrate solution for injection, supplied in a sterile liquid form for intravenous use. It contains the active ingredient sodium glycerophosphate pentahydrate and is marketed in the European Union as a prescription‑only electrolyte replenisher. The product is designed to provide phosphate ions and sodium to support metabolic processes and correct low phosphate levels in clinical settings. Healthcare professionals administer Glycophos under conditions to ensure appropriate electrolyte balance.

Glycophos is indicated for the treatment of conditions where phosphate levels are deficient or depleted.

- Correction of hypophosphatemia in patients receiving parenteral nutrition. - Management of phosphate depletion associated with prolonged intensive care or surgery. - Support of electrolyte balance during renal replacement therapy. - Adjunct therapy in patients with metabolic alkalosis where phosphate repletion is required. - Prevention of phosphate loss in patients on high‑dose diuretics.

Adverse reactions to Glycophos are generally infrequent, but they can be categorized by frequency and severity.

Common: - Mild discomfort, redness, or swelling at the injection site. - Transient nausea, occasional vomiting, or mild gastrointestinal upset. - Temporary elevation of serum calcium without clinical symptoms. - Light‑headedness or mild headache occurring shortly after infusion.

Serious: - Marked hyperphosphatemia that may cause calcium‑phosphate crystal deposition in tissues. - Allergic responses ranging from urticaria and bronchospasm to full anaphylactic shock. - Acute hypotension or cardiovascular instability during rapid infusion. - Development of metabolic acidosis in patients with compromised renal function.

When prescribing Glycophos, clinicians should consider several precautionary measures to minimize risk and ensure safe administration.

- Assess baseline serum phosphate, calcium, and renal function before initiating therapy. - Adjust infusion rate in patients with cardiovascular instability or a history of hypotension. - Monitor electrolyte levels frequently during treatment, especially in renal impairment. - Use caution in individuals with known hypersensitivity to glycerophosphate preparations. - Avoid concurrent administration with calcium‑containing solutions that may precipitate. - Consider alternative phosphate sources in pregnant patients, as safety data are limited.

Glycophos may interact with other agents that affect electrolyte balance or renal function.

Avoid: - Simultaneous infusion of calcium chloride or calcium gluconate, which can cause precipitation. - Co‑administration with high‑dose vitamin D analogues that increase calcium absorption. - Concurrent use with aluminum‑containing antacids, which can bind phosphate and reduce efficacy.

Use with caution: - Concurrent use of loop or thiazide diuretics that alter phosphate excretion. - Administration alongside nephrotoxic drugs such as aminoglycosides or contrast media. - Combination with other phosphate supplements, which may lead to excess serum phosphate. - Concurrent therapy with insulin, which can drive phosphate into cells and affect levels.